Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FEP-TAZ (WCK 4282) in Renal Impairment
NCT02709382Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Foviscu in gram-negative bacterial infections and complicated urinary tract infection (cUTI), sponsored by Wockhardt. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Plasma Concentration at 48 hours and 1 more. Started Mar 2016; status: completed.
02
Drugs
Foviscu
03
Conditions
gram-negative bacterial infectionscomplicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT02709382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709382.